Skip to main content

Advertisement

SpringerLink
Log in

What is the role of therapeutic drug monitoring in antifungal therapy?

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Despite an expanding number of therapeutic options for treating invasive fungal infection (IFI), the mortality rate from these infections remains high. Many risk factors for poor outcome from IFI (eg, the compromised immune status of the host) are not modifiable by the treating clinician. Thus, elevated interest exists in any modifiable factor that might improve outcome. Many of the new antifungal agents have marked variability in drug concentration based on either inconsistent absorption or elimination, leading to very wide interpatient variability. Many agents also have a narrow therapeutic index, meaning a small range between drug levels too low to achieve the desired clinical benefit and high enough to produce unwanted or toxic effects. Therefore, therapeutic drug monitoring is useful to maximize efficacy while minimizing drug toxicity of some antifungal agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Singh N: Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001, 33:1692–1696.

    Article  CAS  PubMed  Google Scholar 

  2. Fungal infections. Am J Transplant 2004, 4(Suppl 10):110–134.

  3. Malani AN, Kauffman CA: Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007, 67:1803–1812.

    Article  CAS  PubMed  Google Scholar 

  4. Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563–571.

    Article  CAS  PubMed  Google Scholar 

  5. Smith J, Safdar N, Knasinski V, et al.: Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570–1572.

    Article  CAS  PubMed  Google Scholar 

  6. Pascual A, Calandra T, Bolay S, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201–211.

    Article  CAS  PubMed  Google Scholar 

  7. Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000, 46:171–179.

    Article  CAS  PubMed  Google Scholar 

  8. Stamm AM, Diasio RB, Dismukes WE, et al.: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987, 83:236–242.

    Article  CAS  PubMed  Google Scholar 

  9. Pasqualotto AC, Howard SJ, Moore CB, Denning DW: Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother 2007, 59:791–793.

    Article  CAS  PubMed  Google Scholar 

  10. Hope WW, Warn PA, Sharp A, et al.: Derivation of an in vitro drug exposure breakpoint for flucytosine against Candida albicans and the impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 2006, 50:3680–3688.

    Article  CAS  PubMed  Google Scholar 

  11. Andes D, van Ogtrop M: In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000, 44:938–942.

    Article  CAS  PubMed  Google Scholar 

  12. Sporanox (itraconazole) capsules [package insert]. Titusville, NJ: Janssen Pharmaceutica Products; 2002.

  13. Glasmacher A, Hahn C, Molitor E, et al.: Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999, 42:591–600.

    Article  CAS  PubMed  Google Scholar 

  14. Hardin TC, Graybill JR, Fetchick R, et al.: Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988, 32:1310–1313.

    CAS  PubMed  Google Scholar 

  15. Lazo de la Vega S, Volkow P, Yeates RA, Pfaff G: Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Drugs Exp Clin Res 1994, 20:69–75.

    CAS  PubMed  Google Scholar 

  16. Jaruratanasirikul S, Kleepkaew A: Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 1997, 52:235–237.

    Article  CAS  PubMed  Google Scholar 

  17. Dominguez-Gill HA, Sanchez NA, Garcia Sanchez MJ: Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. Clin Microbiol Infect 2006, 12(Suppl 7):97–106.

    Article  Google Scholar 

  18. Berenguer J, Ali NM, Allende CM, et al.: Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994, 38:1303–1308.

    CAS  PubMed  Google Scholar 

  19. Denning DW, Tucker RM, Hanson LH, Stevens DA: Treatment of invasive aspergillosis with itraconazole. Am J Med 1989, 86:791–800.

    Article  CAS  PubMed  Google Scholar 

  20. Cartledge JD, Midgely J, Gazzard BG: Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997, 50:477–480.

    Article  CAS  PubMed  Google Scholar 

  21. Denning DW, Tucker RM, Hanson LH, et al.: Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Internal Med 1989, 149:2301–2308.

    Article  CAS  Google Scholar 

  22. Tucker RM, Denning DW, Arathoon EG, et al.: Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Derm 1990, 23(3 Pt 2):593–601.

    Article  CAS  PubMed  Google Scholar 

  23. Tricot G, Joosten E, Boogaerts MA, et al.: Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987, 9(Suppl 1):S94–S99.

    PubMed  Google Scholar 

  24. Boogaerts MA, Verhoef GE, Zachee P, et al.: Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels Mycoses 1989, 32:103–108.

    Article  PubMed  Google Scholar 

  25. Lestner JM, Roberts SA, Moore CB, et al.: Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009, 49:928–930.

    Article  CAS  PubMed  Google Scholar 

  26. Wheat JL, Freifeld AG, Kleiman MB, et al.: Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45:807–825.

    Article  PubMed  Google Scholar 

  27. Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801–1812.

    Article  CAS  PubMed  Google Scholar 

  28. Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53:24–34.

    Article  CAS  PubMed  Google Scholar 

  29. Herbrecht R, Denning D, Patterson T, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408–15.

    Article  CAS  PubMed  Google Scholar 

  30. Vfend (voriconazole) [package insert]. New York: Pfizer, Inc.; 2008.

  31. Schwartz S, Milatovic D, Thiel E.: Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997, 97:663–665.

    Article  CAS  PubMed  Google Scholar 

  32. Hyland R, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003, 31:540–547.

    Article  CAS  PubMed  Google Scholar 

  33. Purkins L, Wood N, Greenhalgh K, et al.: Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003, 56(Suppl 1):10–16.

    Article  CAS  PubMed  Google Scholar 

  34. Service RF: Going from genome to pill. Science 2005, 308:1858–1860.

    Article  CAS  PubMed  Google Scholar 

  35. Trifilio S, Pennick G, Pi J, et al.: Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109:1532–1535.

    Article  CAS  PubMed  Google Scholar 

  36. Mohammedi I, Piens MA, Padoin C, et al.: Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients. Eur J Clin Microbiol Infect Dis 2005, 24:358–360.

    Article  CAS  PubMed  Google Scholar 

  37. Berge M, Guillemain R, Boussaud V, et al.: Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis 2009, 11:211–219.

    Article  CAS  PubMed  Google Scholar 

  38. Trifilio S, Ortiz R, Pennick G, et al.: Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005, 35:509–513.

    Article  CAS  PubMed  Google Scholar 

  39. Mulanovich V, Lewis RE, Raad IA, et al.: Random plasma concentrations of voriconazole decline over time. J Infect 2007, 55:129–130.

    Article  Google Scholar 

  40. Moriyama B, Elinoff J, Danner RL, et al.: Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 2009, 53:1712–1714.

    Article  CAS  PubMed  Google Scholar 

  41. Schwiesow JN, Iseman MD, Peloquin CA: Concomitant use of voriconazole and rifabutin in a patient with multiple infections. Pharmacotherapy 2008, 28:1076–1080.

    Article  CAS  PubMed  Google Scholar 

  42. Andes D, Marchillo K, Stamstad T, Conklin R: In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47:3165–3169.

    Article  CAS  PubMed  Google Scholar 

  43. Pfaller MA, Diekema DJ, Rex JH, et al.: Correlation of MIC with outcome for candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiology 2006, 44:819–826.

    Article  CAS  Google Scholar 

  44. Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003, 36:630–637.

    Article  CAS  PubMed  Google Scholar 

  45. Boyd AE, Modi S, Howard SJ, et al.: Adverse reactions to voriconazole. Clin Infect Dis 2004, 39:1241–1244.

    Article  PubMed  Google Scholar 

  46. Lutsar I, Hodges MR, Tomaszewski K, et al.: Safety of voriconazole and dose individualization. Clin Infect Dis 2003, 36:1087.

    Article  PubMed  Google Scholar 

  47. den Hollander JG, van Arkel C, Rijnders BJ, et al.: Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections. J Antimicrob Chemother 2006, 57:1248–1250.

    Article  CAS  Google Scholar 

  48. Tan K, Brayshaw N, Tomaszewski K, et al.: Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46:235–243.

    Article  CAS  PubMed  Google Scholar 

  49. Zonios DI, Gea-Banacloche J, Childs R, et al.: Hallucinations during voriconazole therapy. Clin Infect Dis 2008, 47:e7–e10.

    Article  CAS  PubMed  Google Scholar 

  50. Walsh TJ, Anaissie EJ, Denning DW, et al.: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327–360.

    Article  CAS  PubMed  Google Scholar 

  51. Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole or fluconazole prophylaxis in severe graft versus host disease. N Engl J Med 2007, 35:335–347.

    Article  Google Scholar 

  52. Courtney R, Wexler D, Radwanski E, et al.: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57:218–222.

    Article  PubMed  Google Scholar 

  53. Ezzet F, Wexler D, Courtney R, et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005, 44:211–220.

    Article  CAS  PubMed  Google Scholar 

  54. Gubbins PO, Krishna G, Sansone-Parsons A, et al.: Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006, 50:1993–1999.

    Article  CAS  PubMed  Google Scholar 

  55. Krishna G, Moton A, Ma L, et al.: Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009, 53:958–966.

    Article  CAS  PubMed  Google Scholar 

  56. Thompson GR 3rd, Rinaldi MG, Pennick G, et al.: Posaconazole therapeutic drug monitoring (TDM): a reference laboratory experience. Antimicrob Agents Chemother 2009, 53:2223–2224.

    Article  CAS  PubMed  Google Scholar 

  57. US Food and Drug Administration: Posaconazole. Available at http://www.fda.gov/cder/foi/nda/2006/022003s000_NoxafilTOC.htm. Accessed May 2009.

  58. Walsh TJ, Raad I, Patterson TF, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Michigan Medical School, 3119 Taubman Center, 1500 East Medical Center Drive, SPC 5378, Ann Arbor, MI, 48109, USA

    Jeannina A. Smith

Authors
  1. Jeannina A. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeannina A. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, J.A. What is the role of therapeutic drug monitoring in antifungal therapy?. Curr Infect Dis Rep 11, 439–446 (2009). https://doi.org/10.1007/s11908-009-0064-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-009-0064-9

Keywords

Search

Navigation